Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide

Vaccine

Volumn 19, Issue 9-10, 2000, Pages 1068-1081

  Frangione Beebe, Melanie ^a   Albrecht, Bjorn ^c   Dakappagari, Naveen ^b   Rose, R Travis ^b   Brooks, Charles L ^c   Schwendeman, Steven P ^d   Lairmore, Michael D ^c   Kaumaya, Pravin T P ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b Department of Entomology   (United States)

^c Department of Psychiatry   (United States)

^d Department of Surgery   (United States)

Author keywords

Biodegradable microspheres; HTLV 1; Peptide vaccines

Indexed keywords

ACH RE3; ADJUVANT; CHIMERIC PROTEIN; EPITOPE; GLYCINE; LEUCINE; MICROSPHERE; N ACETYL GLUCOSAMINE 3YL ACETYL LEVO ALANYL DEXTRO ISOGLUTAMINE; POLYGLACTIN; PROLINE; PROTEIN DERIVATIVE; RECOMBINANT PROTEIN; SERINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ALPHA HELIX; AMINO ACID SEQUENCE; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTICLE; BIODEGRADATION; CONTROLLED STUDY; ENCAPSULATION; FEMALE; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOREACTIVITY; INOCULATION; MEASLES VIRUS; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RABBIT; REVACCINATION; SYNCYTIUM; VACCINE PRODUCTION; VIRUS MORPHOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; EPITOPES; HUMAN T-LYMPHOTROPIC VIRUS 1; MALE; MEASLES VIRUS; MICE; MICE, INBRED ICR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN FOLDING; RABBITS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 0034624035     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00340-6     Document Type: Article

References (59)

1. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease
2. HTLV-I associated myelopathy, a new clinical entity
3. Chronic inflammatory arthropathy associated with HTLV-I
4. T-lymphocyte alveolitis in HTLV-I-associated myelopathy
5. Ocular manifestations in patients infected with human T-lymphotropic virus type I
6. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1
7. Human T-cell leukemia virus type I: Induction of syncytia and inhibition by patients' sera
8. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46
9. Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I)
10. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies
11. Immunoglobulin prophylaxis against HTLV-I in a rabbit model
12. Prevention of human T cell lymphotropic virus type I infection in Japanese macaques by passive immunization
13. Protection of cynomolgus monkeys against infection by human T-cell leukemia virus type-I by immunization with viral env gene products produced in Escherichia coli
14. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene
15. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection
16. Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits
17. Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells
18. Identification of two promiscuous T cell epitopes from tetanus toxin
19. Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans
20. Promiscuous T cell epitopes of tetanus toxin and measles virus enhances immune responses to B cell epitopes of the protein antigen LDH-C4
21. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity
22. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction
23. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies
24. Biodegradable microparticles for oral immunization
25. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems
26. Controlled delivery of diphtheria toxoid using biodegradable poly(D,L-lactide) microcapsules
27. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization
28. Neutralizing activity of human antibodies against the structural protein of human T-cell lymphotropic virus type I
29. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins
30. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera
31. Identification of exposed epitopes on the envelope glycoproteins of human T-cell lymphotropic virus type I (HTLV-I)
32. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1
33. Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization
34. De novo design and immunogenicity of a conformationally-dependent HTLV-1 gp46 epitope
35. Engineered topographic determinants with alpha beta, beta alpha beta, and beta alpha beta alpha topologies show high affinity binding to native protein antigen (lactate dehydrogenase-C4)
36. Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones
37. Determination of the helix and beta form of proteins in aqueous solution by circular dichroism
38. Computed circular dichroism spectra for the evaluation of protein conformation
39. In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotrophic virus type 1
40. Comparative biological responses of rabbits infected with human T-lymphotropic virus type I isolates from patients with lymphoproliferative and neurodegenerative disease
41. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46
42. Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo
43. Prediction of the secondary structure of proteins from their amino acid sequence
44. Opportunities and challenges in the design of implantable biodegradable polymeric systems for the delivery of antimicrobial agents and vaccines
45. Synthetic peptide vaccines: Dream or reality
46. Among all human T-cell leukemia virus type 1 proteins, tax, polymerase, and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response
47. Persistent infection of rabbits with HTLV-I: Patterns of anti-viral antibody reactivity and detection of virus by gene amplification
48. Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-1 retroviral infections
49. Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions
50. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes
51. A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes
52. Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia/lymphoma patient
53. In vivo priming of virus- specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
54. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
55. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide
56. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres
57. CTL responses induced by a single immunization with peptide encapsulated in biodegradable microspheres
58. MHC class-I and class II-restricted processing and presentation of microencapsulated antigens